IL159812A0 - Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core - Google Patents
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release coreInfo
- Publication number
- IL159812A0 IL159812A0 IL15981201A IL15981201A IL159812A0 IL 159812 A0 IL159812 A0 IL 159812A0 IL 15981201 A IL15981201 A IL 15981201A IL 15981201 A IL15981201 A IL 15981201A IL 159812 A0 IL159812 A0 IL 159812A0
- Authority
- IL
- Israel
- Prior art keywords
- ethyl ester
- levodopa ethyl
- release
- decarboxylase inhibitor
- dual
- Prior art date
Links
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 title 2
- 229960001820 etilevodopa Drugs 0.000 title 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 title 1
- 238000013270 controlled release Methods 0.000 title 1
- 239000003954 decarboxylase inhibitor Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30517901P | 2001-07-12 | 2001-07-12 | |
| US34671902P | 2002-01-07 | 2002-01-07 | |
| PCT/US2002/022207 WO2003005968A2 (en) | 2001-07-12 | 2002-07-12 | Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL159812A0 true IL159812A0 (en) | 2004-06-20 |
Family
ID=26974449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15981201A IL159812A0 (en) | 2001-07-12 | 2001-07-12 | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20030152628A1 (xx) |
| AU (1) | AU2002316677A1 (xx) |
| IL (1) | IL159812A0 (xx) |
| WO (1) | WO2003005968A2 (xx) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040241234A1 (en) * | 2003-06-02 | 2004-12-02 | Alpharma, Inc. | Controlled release press-coated formulations of water-soluble active agents |
| ZA200610042B (en) | 2004-06-04 | 2008-06-25 | Xenoport Inc | Levodopa prodrugs, and compositions and uses thereof |
| US7323585B2 (en) * | 2004-06-04 | 2008-01-29 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
| CA2613631A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| BRPI0619425A2 (pt) * | 2005-12-05 | 2011-10-04 | Xenoport Inc | mesilato de pró-fármaco de levedopa, composição farmacêutica, método de preparar (2s)-2- amino-3-(3,4-diidróxi fenil) propanoato de mesilato de (2r)-2- fenil carbonilóxi propila e uso do referido composto |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| US20080070984A1 (en) * | 2006-09-15 | 2008-03-20 | Tran Pierre V | Compositions and Methods of Treating Schizophrenia |
| WO2008076458A1 (en) | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| US7829592B2 (en) * | 2006-12-21 | 2010-11-09 | Xenoport, Inc. | Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| AU2007338631A1 (en) * | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
| AU2008343787B2 (en) | 2007-12-28 | 2014-01-30 | Impax Laboratories, Llc | Controlled release formulations of levodopa and uses thereof |
| BRPI0917444A2 (pt) | 2008-08-15 | 2015-12-01 | Depomed Inc | composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc |
| US8399513B2 (en) | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| CA2740017A1 (en) * | 2008-10-20 | 2010-04-29 | Xenoport, Inc. | Methods of synthesizing a levodopa ester prodrug |
| US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| US8435562B2 (en) | 2009-11-09 | 2013-05-07 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| EP3054929B1 (en) | 2013-10-07 | 2020-08-05 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| EP4299128A3 (en) | 2014-03-13 | 2024-04-17 | Neuroderm Ltd. | Dopa decarboxylase inhibitor compositions |
| EP3291872A4 (en) | 2015-05-06 | 2019-02-13 | SynAgile Corporation | PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US6183778B1 (en) * | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
| IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
| IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
-
2001
- 2001-07-12 IL IL15981201A patent/IL159812A0/xx unknown
-
2002
- 2002-07-12 US US10/194,507 patent/US20030152628A1/en not_active Abandoned
- 2002-07-12 AU AU2002316677A patent/AU2002316677A1/en not_active Abandoned
- 2002-07-12 WO PCT/US2002/022207 patent/WO2003005968A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003005968A2 (en) | 2003-01-23 |
| WO2003005968A3 (en) | 2003-10-16 |
| AU2002316677A1 (en) | 2003-01-29 |
| US20030152628A1 (en) | 2003-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL159812A0 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core | |
| IL159813A0 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core | |
| IL236190B (en) | A preparation containing amikacin and a lipid component | |
| GB0016452D0 (en) | Vitamin K and essential fatty acids | |
| HUP0301841A3 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases and their use | |
| EP1479666A4 (en) | ESTER CONNECTION AND THEIR MEDICAL USE | |
| CZ20011427A3 (cs) | Farmaceutická kompozice s řízeným uvolňovaním obsahující inhibitor CGMP DPE-5 | |
| IL159100A0 (en) | Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor and a monohydric alcohol | |
| IL144214A0 (en) | Benzoheterocycles and their use as mek inhibitors | |
| IL150104A0 (en) | Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor | |
| SG87210A1 (en) | Tertiary-butyl acrylate polymers and their use in photoresist compositions | |
| HUP0402550A3 (en) | Esters and amides as ppar-alpha agonists | |
| EP1551384A4 (en) | R-NSAID ESTERS AND ITS USE | |
| AU5073101A (en) | Lipid composition and use thereof | |
| GB0101035D0 (en) | Formulation and use thereof | |
| AU2002340470A1 (en) | L-dopa ethyl ester salts and uses thereof | |
| AU7122801A (en) | New aporphine esters and their use in therapy | |
| EP1545461A4 (en) | COMBINED ANALGESIC COMPOSITION WITH IMMEDIATE AND PROLONGED RELEASE | |
| IL158908A0 (en) | Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester | |
| GB0222880D0 (en) | Dermatological use and a dermatological preparation | |
| AU1202601A (en) | All-organic corrosion inhibitor composition and uses thereof | |
| PL373315A1 (en) | Preparations containing diformates and short-chain carboxylic acids | |
| AU2003283727A8 (en) | Recording start and stop | |
| AU2002308979A1 (en) | Acrylic esters and use thereof | |
| AUPQ480399A0 (en) | Unsaturated fatty acids and their uses in therapy |